Bupropion 150 mg Extended-Release (XL)Tablets — Generic For Wellbutrin XL — Epic

These highlights do not include all the information needed to use BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (SR) safely and effectively. See full prescribing information for BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (SR).

BUPROPION HYDROCHLORIDE extended-release tablets (SR), for oral use

Initial U.S. Approval: 1985

Warning: Suicidal Thoughts And Behaviors

See full prescribing information for complete boxed warning.

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. (

5.1)

Monitor for worsening and emergence of suicidal thoughts and behaviors. (

5.1)

Indications And Usage

Bupropion Hydrochloride Extended-Release Tablets (SR) are an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD). (

1)

Dosage And Administration

Starting dose: 150 mg/day (

2.1)

General: Increase dose gradually to reduce seizure risk. (

2.1,

5.3)

After 3 days, may increase the dose to 300 mg/day, given as 150 mg twice daily at an interval of at least 8 hours. (

2.1)

Usual target dose: 300 mg/day as 150 mg twice daily. (

2.1)

Maximum dose: 400 mg/day, given as 200 mg twice daily, for patients not responding to 300 mg/day. (

2.1)

Periodically reassess the dose and need for maintenance treatment. (

2.1)

Moderate to severe hepatic impairment: 100 mg daily or 150 mg every other day. (

2.2,

8.7)

Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. (

2.2,

8.7)

Renal impairment: Consider reducing the dose and/or frequency. (

2.3,

8.6)

Dosage Forms And Strengths

Tablets: 100 mg, 150 mg, 200 mg. (

3)

Contraindications

Seizure disorder. (

4,

5.3)

Current or prior diagnosis of bulimia or anorexia nervosa. (

4,

5.3)

Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. (

4,

5.3)

Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with Bupropion Hydrochloride Extended-Release Tablets (SR) or within 14 days of stopping treatment with Bupropion Hydrochloride Extended-Release Tablets (SR). Do not use Bupropion Hydrochloride Extended-Release Tablets (SR) within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start Bupropion Hydrochloride Extended-Release Tablets (SR) in a patient who is being treated with linezolid or intravenous methylene blue. (

4,

7.6)

Known hypersensitivity to bupropion or other ingredients of Bupropion Hydrochloride Extended-Release Tablets (SR). (

4,

5.8)

Warnings And Precautions

• Neuropsychiatric adverse events during smoking cessation: Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with bupropion for the occurrence of such symptoms and instruct them to discontinue bupropion and contact a healthcare provider if they experience such adverse events. ( 5.2)
• Seizure risk: The risk is dose-related. Can minimize risk by gradually increasing the dose and limiting daily dose to 400 mg. Discontinue if seizure occurs. ( 4, 5.3, 7.3)
• Hypertension: Bupropion hydrochloride extended-release tablets (SR) can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during treatment. ( 5.4)
• Activation of mania/hypomania: Screen patients for bipolar disorder and monitor for these symptoms. ( 5.5)
• Psychosis and other neuropsychiatric reactions: Instruct patients to contact a healthcare professional if such reactions occur. ( 5.6)
• Angle-closure glaucoma: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. ( 5.7)

• Neuropsychiatric adverse events during smoking cessation: Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with bupropion for the occurrence of such symptoms and instruct them to discontinue bupropion and contact a healthcare provider if they experience such adverse events. ( 5.2)
• Seizure risk: The risk is dose-related. Can minimize risk by gradually increasing the dose and limiting daily dose to 400 mg. Discontinue if seizure occurs. ( 4, 5.3, 7.3)
• Hypertension: Bupropion hydrochloride extended-release tablets (SR) can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during treatment. ( 5.4)
• Activation of mania/hypomania: Screen patients for bipolar disorder and monitor for these symptoms. ( 5.5)
• Psychosis and other neuropsychiatric reactions: Instruct patients to contact a healthcare professional if such reactions occur. ( 5.6)
• Angle-closure glaucoma: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. ( 5.7)

Neuropsychiatric adverse events during smoking cessation: Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with bupropion for the occurrence of such symptoms and instruct them to discontinue bupropion and contact a healthcare provider if they experience such adverse events. (

5.2)

Seizure risk: The risk is dose-related. Can minimize risk by gradually increasing the dose and limiting daily dose to 400 mg. Discontinue if seizure occurs. (

4,

5.3,

7.3)

Hypertension: Bupropion hydrochloride extended-release tablets (SR) can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during treatment. (

5.4)

Activation of mania/hypomania: Screen patients for bipolar disorder and monitor for these symptoms. (

5.5)

Psychosis and other neuropsychiatric reactions: Instruct patients to contact a healthcare professional if such reactions occur. (

5.6)

Angle-closure glaucoma: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. (

5.7)

Adverse Reactions

Most common adverse reactions (incidence ≥5% and ≥2% more than placebo rate) are: headache, dry mouth, nausea, insomnia, dizziness, pharyngitis, constipation, agitation, anxiety, abdominal pain, tinnitus, tremor, palpitation, myalgia, sweating, rash, and anorexia. (

6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Epic Pharma, LLC at 1-888-374-2791 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

CYP2B6 inducers: Dose increase may be necessary if coadministered with CYP2B6 inducers (e.g., ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, and phenytoin) based on clinical response, but should not exceed the maximum recommended dose. (

7.1)

Drugs metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). Consider dose reduction when using with bupropion. (

7.2)

Digoxin: May decrease plasma digoxin levels. Monitor digoxin levels. (

7.2)

Drugs that lower seizure threshold: Dose bupropion hydrochloride extended-release tablets (SR) with caution. (

5.3,

7.3)

Dopaminergic drugs (levodopa and amantadine): CNS toxicity can occur when used concomitantly with bupropion hydrochloride extended-release tablets (SR). (

7.4)

MAOIs: Increased risk of hypertensive reactions can occur when used concomitantly with bupropion hydrochloride extended-release tablets (SR). (

7.6)

Drug-laboratory test interactions: Bupropion hydrochloride extended-release tablets (SR) can cause false-positive urine test results for amphetamines. (

7.7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 4/2026